Search Results

Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the signing of agreements with affiliates of Santen Pharmaceutical Co., Ltd. (“Santen”) under which Harrow will acquire certain U.S. and Canadian commercial rights for the following branded products from Santen:

Santen Pharmaceutical Co., Ltd. announced that it has signed licensing agreements and an asset transfer agreement with two U.S. companies.

Santen Canada Inc., a subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), today announced the approval of Cationorm® Plus by Health Canada.

Santen’s Verkazia ® (Cyclosporine Ophthalmic Emulsion) 0.1% Now Available for the Treatment of Vernal Keratoconjunctivitis in Children and Adults in the United States.

Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), and UBE Corporation (UBE) today announced that the U.S. Food and Drug Administration (FDA) has approved OMLONTI® (omidenepag isopropyl ophthalmic solution) 0.002% eye drops for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension.

Santen Canada Inc., a subsidiary of Santen Pharmaceutical Co., Ltd., a global company focused exclusively on ophthalmology, announced the approval of PRESERFLOTM MicroShunt by Health Canada.

Global biopharmaceutical firms Santen SA and Sydnexis have entered an exclusive licensing deal for a drug formulation that aims to treat progressive myopia.

Aerie Pharmaceuticals, Inc. announced that Aerie and Santen have entered into an exclusive development and commercialization agreement for Rhopressa®/Rhokiinsa® 0.02% and Rocklatan®/Roclanda® 0.02%/0.005%.